Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open Label Dose Escalation Study Evaluate The Safety Of a Single Escalating Dose Of NX-CP105 (Human Adult Bone Marrow Derived Somatic Cells [hABM-SC] Administered by Endomyocardial Injection To Cohorts Of Adults 30-60 Days Following Acute Myocardial Infarction

NCT00361855 is registered in ClinicalTrials.gov with Neuronyx as lead sponsor.

NCT NCT00361855
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00361855 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open Label Dose Escalation Study Evaluate The Safety Of a Single Escalating Dose Of NX-CP105 (Human Adult Bone Marrow Derived Somatic Cells [hABM-SC] Administered by Endomyocardial Injection To Cohorts Of Adults 30-60 Days Following Acute Myocardial Infarction
Lead sponsor
Neuronyx
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2006
Completion date
Not reported
Enrollment
18 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

myocardial infarction